Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 430847, 11 pages
Review Article

Wharton’s Jelly Derived Mesenchymal Stem Cells: Future of Regenerative Medicine? Recent Findings and Clinical Significance

1Department of Histology and Embryology, Center for Biostructure Research, Medical University of Warsaw, Chalubinskiego 5, 02-004 Warsaw, Poland
2Centre for Preclinical Research and Technology, Banacha 1b, 02-097 Warsaw, Poland
3Polish Stem Cell Bank, Grzybowska 2/41, 00-131 Warsaw, Poland

Received 12 December 2014; Accepted 2 March 2015

Academic Editor: Josep Maria Pujal

Copyright © 2015 Ilona Kalaszczynska and Katarzyna Ferdyn. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Around 5 million annual births in EU and 131 million worldwide give a unique opportunity to collect lifesaving Wharton’s jelly derived mesenchymal stem cells (WJ-MSC). Evidences that these cells possess therapeutic properties are constantly accumulating. Collection of WJ-MSC is done at the time of delivery and it is easy and devoid of side effects associated with collection of adult stem cells from bone marrow or adipose tissue. Likewise, their rate of proliferation, immune privileged status, lack of ethical concerns, nontumorigenic properties make them ideal for both autologous and allogeneic use in regenerative medicine applications. This review provides an outline of the recent findings related to WJ-MSC therapeutic effects and possible advantage they possess over MSC from other sources. Results of first clinical trials conducted to treat immune disorders are highlighted.